Lupus erythematosus - Sarkanā Vilkēde
☆ 2022. gada Stiftung Warentest rezultātos no Vācijas patērētāju apmierinātība ar ModelDerm bija tikai nedaudz zemāka nekā ar maksas telemedicīnas konsultācijām.
Izskatās kā nedaudz purpursarkana eritēma.
Tauriņa izsitumi, kas parasti parādās uz sejas.
References
Cutaneous lupus erythematosus (CLE) identificēšana un klasificēšana rada diagnostikas izaicinājumus, atšķirot to no systemic lupus erythematosus ar ādas iesaistīšanos. Jaunākie pētījumi atklāja CLE pamatā esošos ģenētiskos, vides un imunoloģiskos faktorus. Īpaši narkotiku indukcija ir kļuvusi par vienu no svarīgākajiem CLE izraisītājiem. Ārstēšana ietver lokālu un sistēmisku terapiju, tostarp daudzsološas bioloģiskas zāles, piemēram, belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 , kuru efektivitāte ir pierādīta klīniskajos pētījumos.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) aptver dažādas ādas problēmas, no kurām dažas var būt saistītas ar plašākām veselības problēmām. Tas ir iedalīts dažādos veidos, piemēram, acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . CCLE ietver discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus ir autoimūnu slimību grupa, kas var ietekmēt dažādas ķermeņa daļas. Daži veidi, piemēram, systemic lupus erythematosus (SLE) , ietekmē vairākus orgānus, savukārt citi, piemēram, cutaneous lupus erythematosus (CLE) , galvenokārt ietekmē ādu. Mēs iedalām dažādus CLE veidus, pamatojoties uz klīnisko pazīmju kombināciju, audu izmeklēšanu un asins analīzēm, taču starp indivīdiem ir daudz atšķirību. Ādas problēmas bieži rodas tādu faktoru dēļ kā saules gaismas iedarbība, smēķēšana vai noteiktas zāles.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
sarkanā vilkēde (lupus erythematosus) cēlonis nav skaidrs. Identiskiem dvīņiem, ja viens tiek ietekmēts, pastāv 24% iespēja, ka arī otrs tiks ietekmēts. Tiek uzskatīts, ka risku palielina arī sieviešu dzimuma hormoni, saules gaisma, smēķēšana, D vitamīna deficīts un noteiktas infekcijas.
Ārstēšana var ietvert NPL, kortikosteroīdus, imūnsupresantus, hidroksihlorokvīnu un metotreksātu. Lai gan kortikosteroīdi ir efektīvi, ilgstoša lietošana izraisa blakusparādības.